Medical Management References:
1. Zar, F.A., et al., A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis, 2007. 45(3): p. 302-7.
2. Johnson, S., et al., Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis, 2014. 59(3): p. 345-54.
3. Cornely, O.A., et al., Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a
double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis, 2012. 12(4): p. 281-9.
4. Louie, T.J., et al., Fidaxomicin versus Vancomycin for Clostridium difficile Infection. New England Journal of Medicine, 2011. 364(5): p. 422-431.
5. Goldenberg, S.D., et al., The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis, 2016. 35(2): p. 251-9.
6. McDonald, L.C., et al., Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the
Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis, 2018.
DISCLAIMER: The comments made during these videos are offered only for general informational and educational purposes. Dr. Feuerstadt's comments are not offered as and do not constitute medical advice or legal opinions and no statement made during these videos is intended to replace your independent and professional judgment.